We report a case of successful high-dose intravenous immunoglobulin (IVIG) use in a patient with refractory polyarteritis nodosa (PAN). Treatments with prednisolone (PSL) and various types of immunosuppressants including methotrexate (MTX) and intravenous cyclophosphamide (IVCY) were unsuccessful, and then, high-dose IVIg therapy was added. High-dose IVIG therapy improved all symptoms including...

OBJECTIVE The purpose of this study was to compare the efficacy and side effects of intravenous immunoglobulin (IVIG) with intravenous anti-D immunoglobulin for treatment of newly diagnosed acute childhood Idiopathic thrombocytopenic purpura (ITP). METHODS Children (6 months to 14 years) with newly diagnosed acute ITP and platelet count below 20,000/ microL were randomized to receive single d...

Background Kawasaki disease (KD) is the second most common childhood vasculitis and one of the main causes of acquired heart disease in children. Recent work focuses on the early diagnostic importance of those risk factors that indicate resistance to intravenous immunoglobulin (IVIG) treatment. The objectives of this study were to identify clinical, laboratory and/or instrumental factors that c...

    Background: Economic evaluation of subcutaneous immunoglobulin therapy (SCIG) is important, and it has recently been used for treatment of patients with primary immunodeficiency (PID) diseases, and can improve allocation of resources in health care systems. The present research aimed at providing an economic assessment of SCIG and IVIG (intravenous immunoglobulin therapy) adm...

CONTEXT Intravenous immunoglobulin (IVIG) enhances immune homeostasis by modulating expression and function of Fc receptors, interfering with activation of complement and production of cytokines, providing anti-idiotypic antibodies, and affecting the activation and effector functions of T and B cells. These mechanisms may explain the effectiveness of IVIG in autoimmune neuromuscular disorders. ...

https://e-kcj.org Downie et al.1) defined intravenous immunoglobulin (IVIG) resistance in patients with Kawasaki disease (KD) as any patient who receives a second dose of IVIG and had a fever (body temperature [BT] >38.0°C) since finishing the first IVIG dose (2 g/kg). In addition, patients who do not respond to IVIG (BT ≥37.5°C more than 24 hours after the end of IVIG infusion) seem to develop...

In recent years, human-driven intravenous immunoglobulins (IVIG) administered intravenously have been widely used in treatment of many diseases. Intravenous immunoglobulin is obtained from human-driven plasma pools as in other plasma-driven products and IVIG preperations contain structurally and functionally intact immunoglobulin. Intravenous immunoglobulin was approved by FDA (Food and Drug Ad...

Some patients with autoimmune and inflammatory diseases treated with intravenous immunoglobulin G (IVIg) as a first line therapy are refractory. Identification of predictive biomarker(s) to segregate responders and non-responders to IVIg therapy remains critical. A number of biomarkers, particularly in Kawasaki disease, have shown potential for predicting response to IVIg.

Though the indication mentioned for resorting to plasmapheresis in the report is the unaffordability of intravenous immunoglobulin (IVIG) therapy, I wish to highlight other important reasons for preferring plasmapheresis over IVIG. Firstly, IVIG is known to exert its immunomodulatory effects for a prolonged period of time. The mean duration of action of IVIG is 53 days and the half life of immu...